Bayer offers additional rFVIII products.
Kovaltry and Jivi are available to meet the needs of patients currently taking Kogenate FS.
All adult and adolescent patients (12 and older) currently taking Kogenate FS who are interested in an extended half-life (EHL) product should talk to their healthcare provider about transitioning to Jivi.
For adults and adolescents ≥12Learn more
Most Kogenate FS patients who transition to Jivi or Kovaltry can receive either product at little to no out-of-pocket cost, through the Access Services by Bayer program.*†
Click here to view the Co-Pay & Support Programs.
As your go-to resource, Bayer Reps are ready to provide the information and resources to support you and your patients during this transition.
Click here to locate the Bayer Rep nearest to you.
Call our dedicated Kogenate FS Hotline for more information. Live helpline support is available 8:30 AM - 8:00 PM ET Monday-Friday.
*Co-pay program support is available for up to 1 year. Can include any out-of-pocket prescription costs, such as co-pay and co-insurance. Up to $20,000 in co-pay assistance available per year. Eligible patients will be auto-enrolled every January.
†Patients who are enrolled in any type of government insurance are not eligible. Bayer reserves the right to rescind, revoke, or amend this offer without notice at any time.
‡Formulary status is believed to be accurate as of January 1, 2022 but cannot be guaranteed. Formulary status for national plans may not reflect plan variation at the local level. Lower co-pay costs do not necessarily reflect a cost advantage in the outcome of the condition treated because there are other variables that affect relative cost. Formulary status does not imply a comparison of efficacy, safety, or dosing.
§Jivi coverage includes pharmacy and medical lives across commercial (99%), fee-for-service Medicaid (100%), Managed Medicaid (100%) & Medicare Advantage (100%). Percentage represents the coverage within the book of business. n=1,518, 51, 369, 748. Kovaltry coverage includes pharmacy and medical lives across commercial (99%), fee-for-service Medicaid (100%), Managed Medicaid (100%) & Medicare Advantage (100%). Percentage represents the plan coverage within the book of business: n=1,798; 51; 410; 1,112.
KOGENATE FS is an Antihemophilic Factor (Recombinant) indicated for:
KOVALTRY Antihemophilic Factor (Recombinant) is a recombinant human DNA sequence derived, full length Factor VIII concentrate indicated for use in adults and children with hemophilia A for:
JIVI antihemophilic factor (recombinant), PEGylated-aucl, is a recombinant DNA-derived, Factor VIII concentrate indicated for use in previously treated adults and adolescents (12 years of age and older) with hemophilia A (congenital Factor VIII deficiency) for:
KOGENATE FS, KOVALTRY, and JIVI are not indicated for the treatment of von Willebrand disease.
In clinical trials with: